The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer [0.03%]
新辅助化疗与初期手术在三阴性卵巢癌管理中的作用比较
T Van Gorp,F Amant,P Neven et al.
T Van Gorp et al.
Cytoreduction and intraperitoneal chemotherapy for carcinomatosis from gastric cancer [0.03%]
胃癌腹膜转移的减瘤术和腹腔化疗
Y Yonemura,E Bando,T Kawamura et al.
Y Yonemura et al.
Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma [0.03%]
细胞减灭术和HIPEC治疗恶性腹膜间皮瘤的临床结果
H R Alexander,N Hanna,J F Pingpank
H R Alexander
Taken together, these reports provide very provocative and encouraging data that have prompted some to conclude that cytoreduction and HIPEC represents a "new standard of care" for patients with MPM [26]. Certainly, for selected patients wh...
T J Miner
T J Miner
Clinical results of cytoreduction and HIPEC in pseudomyxoma peritonei [0.03%]
细胞减灭术和HIPEC治疗假性黏液瘤的临床疗效分析
N J Lutton,B J Moran
N J Lutton
HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin [0.03%]
用于治疗腹膜癌的异基因化疗加奥沙利铂疗法
D Elias,M Pocard,D Goere
D Elias
Clinical Trial
Cancer treatment and research. 2007:134:303-18. DOI:10.1007/978-0-387-48993-3_19 2007
Handling of chemotherapeutic drugs in the or: hazards and safety considerations [0.03%]
化疗药物在门诊手术室的处理：危险性及安全防护措施
T Kiffmeyer,C Hadtstein
T Kiffmeyer
M H Dahlke,H J Schlitt,P Piso
M H Dahlke